news out! http://ih.advfn.com/p.php?pid=nmona&a
Post# of 30027
http://ih.advfn.com/p.php?pid=nmona&artic...dw=1126416
still have to read it myself.
Quote:
Amarantus Provides Update on Capital Restructuring and
Announces Participation in RESI JPM 2018
Convertible securities holders grant 45-day extension to complete Tender Exchange
Elto Pharma recruiting seasoned management to lead "Go-Public" transaction
Management attending RESI JPM 2018 on Tuesday, January 9, 2018
SAN FRANCISCO, California -- January 9, 2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings,Inc.(USOTCPK: AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that a controlling majority of its secured creditors and convertible preferred securities holders have agreed to a 45-day extension to complete the Tender Exchange of convertible securities under the Forbearance and Capital Restructuring Agreements initially disclosed by the Company on November 17, 2017. Under the terms of the extension, Amarantus now has until February 24th, 2018 to complete the Tender Exchange. The moratorium on conversions of securities into common stock remains in place until that date.
Based upon discussions Amarantus' management and board have engaged in since the initial public disclosure of the pending Tender Exchange, Amarantus believes that its wholly-owned subsidiary Elto Pharma, Inc. is well positioned to source independent financing to complete the proposed Phase 2b clinical study of Eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). Given the valuations attributed to initial public offerings (IPOs) for companies with assets comparable to Elto Pharma, the Company has initiated the recruiting process for new management to lead the Elto Pharma subsidiary through a Go-Public transaction to raise sufficient capital to complete the next phase of clinical development for Eltoprazine in PD-LID. Eltoprazine has successfully completed initial Phase 2 studies in PD-LID, Agitation in Alzheimer's disease, and Adult ADHD. The Company and each of its subsidiaries are now eligible to use funding mechanisms created under the JOBS Act to achieve their strategic funding objectives.
The successful sourcing of independent funding for Elto Pharma will provide a framework for the sourcing of independent financing for Amarantus' other wholly-owned subsidiaries Cutanogen Corporation and MANF Therapeutics, Inc. As a result, the Company is also beginning the recruitment process for management teams for each of these subsidiaries. The independent sourcing of capital for each of Amarantus' subsidiaries will dramatically reduce the Company's need for ongoing funding, thereby limiting further dilution at the parent-company level.
Amarantus will be participating in Redefining Early Stage Investments (RESI) JPM2018 on Tuesday January 9, 2018 at the Marines' Memorial Club & Hotel in San Francisco, CA.